Drug and disease signature integration identifies synergistic combinations in glioblastoma

Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed S...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathias, Vasileios, Jermakowicz, Anna M., Maloof, Marie E., Forlin, Michele, Walters, Winston, Suter, Robert K., Durante, Michael A., Williams, Sion L., Harbour, J. William, Volmar, Claude-Henry, Lyons, Nicholas J., Wahlestedt, Claes, Graham, Regina M., Ivan, Michael E., Komotar, Ricardo J., Sarkaria, Jann N., Subramanian, Aravind, Golub, Todd R., Schürer, Stephan C., Ayad, Nagi G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294341/
https://www.ncbi.nlm.nih.gov/pubmed/30552330
http://dx.doi.org/10.1038/s41467-018-07659-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294341/
https://www.ncbi.nlm.nih.gov/pubmed/30552330
http://dx.doi.org/10.1038/s41467-018-07659-z

Ejemplares similares